[Edaily Reporter Shin Ha-yeon] #Medipost announced on the 4th that it has decided to make a cash investment of 22.734 billion won in its U.S. subsidiary, MEDIPOST, Inc. The scale of this investment corresponds to 9.1% of Medipost’s equity.
The number of shares to be acquired is 15 million, and following the acquisition, Medipost’s ownership stake in MEDIPOST, Inc. will remain at 100%. The scheduled acquisition date is the 30th of this month.
The investment funds are expected to be used for Phase 3 clinical research and development (R&D) costs and operating expenses to advance the commercialization of "Cartistem," a stem cell therapy for knee osteoarthritis, in the United States.
The number of shares to be acquired is 15 million, and following the acquisition, Medipost’s ownership stake in MEDIPOST, Inc. will remain at 100%. The scheduled acquisition date is the 30th of this month.
The investment funds are expected to be used for Phase 3 clinical research and development (R&D) costs and operating expenses to advance the commercialization of "Cartistem," a stem cell therapy for knee osteoarthritis, in the United States.
